Burrill Starts Cleveland BioLabs (CBLI) at Market Outperform
Tweet
Share
E-mail
Get Alerts CBLI Hot Sheet
Price: $3.17 --0%
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Burrill initiates coverage on Cleveland BioLabs (NASDAQ: CBLI) with a Market Outperform. PT $4.00.
The firm comments, "We believe that the company's lead program, Entolimod, has the potential to be used as an antidote for the treatment of Acute Radiation Syndrome (ARS). CBLI aims to secure procurement contracts from the U.S. government. Not entirely reliant on government funding, CBLI has initiated a number of oncology programs, which range from pre-clinical testing to Phase 1/2 development."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.31 yesterday.
The firm comments, "We believe that the company's lead program, Entolimod, has the potential to be used as an antidote for the treatment of Acute Radiation Syndrome (ARS). CBLI aims to secure procurement contracts from the U.S. government. Not entirely reliant on government funding, CBLI has initiated a number of oncology programs, which range from pre-clinical testing to Phase 1/2 development."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- JPMorgan Starts Universal Store Holdings (UNI:AU) at Overweight
- JPMorgan Starts Accent Group Ltd. (AX1:AU) at Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
